HORIZON: Rocatinlimab Effective in Adults With Atopic Dermatitis
WEB18 hours ago · The randomized, double-blind, placebo-controlled ROCKET HORIZON study (ClinicalTrials.gov Identifier: NCT05651711) evaluated the safety and efficacy of rocatinlimab, an anti-OX40 antibody, in adults with moderate to severe atopic dermatitis. Study participants (N=726) were randomly assigned to receive rocatinlimab or placebo administered as a ...
Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 …
WEB2 days ago · Rocatinlimab Met Co-Primary Endpoints of vIGA-AD TM 0/1 with a ≥ 2-Point Reduction from Baseline, EASI-75, and All Key Secondary Endpoints; HORIZON is the First of Eight Phase 3 Trials in the ...
Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase
WEB2 days ago · Rocatinlimab Met Co-Primary Endpoints of vIGA-AD TM 0/1 with a ≥ 2-Point Reduction from Baseline, EASI-75, and All Key Secondary Endpoints; HORIZON is the First of Eight Phase 3 Trials in the ROCKET Program; TOKYO, Sept. 25, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (Kyowa Kirin) (TSE:4151) (President and CEO: Masashi Miyamoto) announced top-line results of the Phase 3 ROCKET HORIZON trial ...
Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 …
WEB3 days ago · Rocatinlimab Met Co-Primary Endpoints of vIGA-AD™ 0/1 with a ≥ 2-Point Reduction from Baseline, EASI-75, and All Key Secondary Endpoints HORIZON is the First of Eight Phase 3 Trials in the ROCKET Program Tokyo, Japan, September 25, 2024 -- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and CEO: Masashi Miyamoto) announced top-line results of […]
Amgen reports success for eczema and myasthenia gravis …
WEB3 days ago · In the Phase 3 trials, dubbed Horizon and Mint, the California company tested therapies for eczema and myasthenia gravis, respectively. In its eczema trial, Amgen reported that its drug ...
Rocatinlimab exhibits positive results in phase 3 study for atopic ...
WEB2 days ago · Rocatinlimab exhibited promising results in the phase 3 ROCKET HORIZON trial for the treatment of moderate to severe atopic dermatitis, Kyowa Kirin announced in a press release. Rocatinlimab is an ...
New Treatment for Moderate to Severe Atopic Dermatitis Shows …
WEBDec 9, 2022 · The results support rocatinlimab as a safe and effective treatment for moderate to severe atopic dermatitis, with potentially long-lasting efficacy and disease modification. Adverse events reported were generally similar between rocatinlimab groups.
Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis
WEBIn their multicentre, double-blind, placebo-controlled phase 2b study, Emma Guttman-Yassky and colleagues showed the efficacy and safety of subcutaneous rocatinlimab versus subcutaneous placebo for the treatment of moderate-to-severe atopic dermatitis. 1 Although the findings of this study are novel and encouraging, there are a few limitations ...
An anti-OX40 antibody to treat moderate-to-severe atopic …
WEBJan 21, 2023 · We found one phase 1, single-centre, open-label study that investigated three doses of the anti-OX40 antibody KHK4083 (now rocatinlimab) for 4 weeks in a cohort of 22 Japanese patients with moderate-to-severe atopic dermatitis (NCT03096223).
WEBRocatinlimab (KHK4083/AMG451) an investigational, is a potential first-in-class, anti-OX40 monoclonal antibody that inhibits and reduces the number of OX40+ pathogenic T cells responsible for driving systemic and local AD inflammatory responses.
- Some results have been removed